



UNITED STATES
PATENT AND
TRADEMARK OFFICE

Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/754,032	01/03/2001	Matthew P. Scott	CIBT-P10-203

28120
ROPS & GRAY
ONE INTERNATIONAL PLACE
BOSTON, MA 02110-2624

RECEIVED

MAR 06 2003

TECH CENTER 1600/2900

CONFIRMATION NO. 2036

FORMALITIES LETTER



OC000000009499120

Date Mailed: 02/10/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

PART 2 - COPY TO BE RETURNED WITH RESPONSE



71B
71A

1646

Docket No.: CIBT-P10-203
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Plant Application of:
Matthew P. Scott, et al.

Application No.: 09/754032

Group Art Unit: 1646

Filed: January 3, 2001

Examiner: Not Yet Assigned

For: PATCHED GENES AND USES RELATED
THERETO

RECEIVED

MAR 06 2003

TECH CENTER 1600/2000

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATION CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Customer Service Center
Initial Patent Examination Division
Commissioner for Patents
Washington, DC 20231

Dear Sir:

This is in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated February 10, 2003 (copy enclosed).

On July 26, 2001, Applicants filed a Transmittal of Sequence Listing in Computer Readable Form in Compliance with 37 C.F.R. §§ 1.821(e) and (f). Enclosed are copies of the filing and the PTO-stamped return postcard.

Accordingly, Applicants assert that all formalities were complete on July 26, 2001.

Applicants respectfully request express examination of the above-referenced patent application.

No fee is believed due with this submission. However, if a fee is due, please charge our Deposit Account No. 18-1945, under Order No. CIBT-P10-203 from which the undersigned is authorized to draw.

Dated: February 27, 2003

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735


(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Customer Service Center, Initial Patent Examination Division, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: February 27, 2003

Signature:  (Mary Jane DiPalma)